N-(2-chloro-3-phenylpropyl)-N-methylprop-2-yn-1-amine | 1146972-98-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(2-chloro-3-phenylpropyl)-N-methylprop-2-yn-1-amine
• 英文别名: 2-chloro-N-methyl-3-phenyl-N-prop-2-ynylpropan-1-amine
• CAS: 1146972-98-6
• 化学式: C₁₃H₁₆ClN
• 分子量: 221.73
• InChiKey: YGGJVHIRWPAHFA-UHFFFAOYSA-N

物化性质

• 沸点：
  293.3±30.0 °C(predicted)
• 密度：
  1.068±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-N-(1-chloro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine 、 N-(2-chloro-3-phenylpropyl)-N-methylprop-2-yn-1-amine 在 Kryptofix222[18F]钾盐 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.33h， 生成 N-[(2S)-1-[18F]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine 、 N-(2-(18F)fluoro-3-phenylpropyl)-N-methylprop-2-yn-1-amine
  参考文献：
  名称：

  [EN] COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS
  [FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE CADRE D'IMAGERIE, DE DIAGNOSTIC ET/OU DE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL OU DE TUMEURS

  摘要：

  公开号：

  WO2009052970A3
• 作为产物：
  描述：

  (S)-2-(N,N-methylpropargylamino)-3-phenylpropan-1-ol 在 三乙胺 、 甲基磺酰氯 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 (S)-N-(1-chloro-3-phenylpropan-2-yl)-N-methylprop-2-yn-1-amine 、 N-(2-chloro-3-phenylpropyl)-N-methylprop-2-yn-1-amine
  参考文献：
  名称：

  [EN] COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS
  [FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE CADRE D'IMAGERIE, DE DIAGNOSTIC ET/OU DE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL OU DE TUMEURS

  摘要：

  公开号：

  WO2009052970A3

文献信息

• COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS
  申请人：Lehmann Lutz

  公开号：US20100233086A1

  公开（公告）日：2010-09-16

  This invention relates to novel compounds suitable for labelling or already labelled by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及适用于标记或已经通过18F标记的新型化合物，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物，组合物或试剂盒用于正电子发射断层摄影（PET）的诊断成像的用途。
• Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2374779A1

  公开（公告）日：2011-10-12

  This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及适合标记或已经标记 18F 的新型化合物、制备此类化合物的方法、包含此类化合物的组合物、包含此类化合物或组合物的试剂盒以及此类化合物、组合物或试剂盒在正电子发射断层扫描（PET）诊断成像中的用途。
• Synthesis of Three Novel Fluorine-18 Labeled Analogues of <scp>l</scp>-Deprenyl for Positron Emission Tomography (PET) studies of Monoamine Oxidase B (MAO-B)
  作者：Sangram Nag、Lutz Lehmann、Tobias Heinrich、Andrea Thiele、Georg Kettschau、Ryuji Nakao、Balázs Gulyás、Christer Halldin

  DOI：10.1021/jm200710b

  日期：2011.10.27

  The aim in this project was to synthesize and to study fluorine-18 labeled analogues of L-deprenyl which bind selectively to the enzyme monoamine oxidase B (MAO-B). Three fluorinated L-deprenyl analogues have been generated in multistep organic syntheses. The most promising fluorine-18 compound N-[(2S)-1-[F-18]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine (4c) was synthesized by a one-step fluorine-18 nucleophilic substitution reaction. Autoradiography on human brain tissue sections demonstrated specific binding for compound 4c to brain regions known to have a high content of MAO-B. In addition, the corresponding nonradioactive fluorine-19 compound (13) inhibited recombinant human MAO-B with an IC50 of 170.5 +/- 29 n/v1 but did not inhibit recombinant human MAO-A (IC50 > 2000 nM), demonstrating its specificity. Biodistribution of 4c in mice showed high initial brain uptake leveling at 5.4 +/- 0.04%ID/g after 2 min post injection. In conclusion, compound 4c is a specific inhibitor of MAO-B with high initial brain uptake in mice and is, therefore, a candidate for further investigation in PET.
• COMPOUNDS FOR USE IN IMAGING, DIAGNOSING, AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS
  申请人：Piramal Imaging SA

  公开号：EP2217549B1

  公开（公告）日：2017-04-19
• US8784775B2
  申请人：——

  公开号：US8784775B2

  公开（公告）日：2014-07-22